Shots:
John spoke about the results from the P-II MOUNTAINEER Trial evaluating its lead candidate in mCRPC
He also talked about TUKYSA (tucatinib) in combination with trastuzumab as a potential treatment for mCRPC
The interview gives a deeper understanding of Seagen’s vision of developing transformative cancer treatment options
Smriti: Share the details (ROA, MOA & formulations)…
